Loading...
Atezolizumab plus bevacizumab versus sorafenib as first‐line treatment for unresectable hepatocellular carcinoma: a cost‐effectiveness analysis
Saved in:
| Published in: | Cancer Commun (Lond) |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
John Wiley and Sons Inc.
2020
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7743015/ https://ncbi.nlm.nih.gov/pubmed/33159490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cac2.12110 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|